{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:49:26Z","timestamp":1791362966966,"version":"4.3.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.euroneuro.2012.11.004","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T06:47:14Z","timestamp":1361515634000},"page":"956-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Equipercentile linking of the BPRS and the PANSS"],"prefix":"10.1016","volume":"23","author":[{"given":"S.","family":"Leucht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.euroneuro.2012.11.004_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action\u2014a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.11.004_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","article-title":"Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial","volume":"7","author":"Beasley","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind fixed dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.euroneuro.2012.11.004_bib13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.11.004_bib2","first-page":"48","article-title":"The Brief Psychiatric Rating Scale (BPRS): a comprehensive review","volume":"11","author":"Hedlund","year":"1980","journal-title":"J. Oper. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.11.004_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.11.004_bib16","series-title":"Test Equating. Methods and Practices","author":"Kolen","year":"1995"},{"key":"10.1016\/j.euroneuro.2012.11.004_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of BPRS scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.11.004_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.11.004_bib18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.11.004_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.11.004_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/01466210122032172","article-title":"EQUIPERCENT: a SAS program for calculating equivalent scores using the equipercentile method","volume":"25","author":"Price","year":"2001","journal-title":"Appl. Psychol. Meas."},{"issue":"4","key":"10.1016\/j.euroneuro.2012.11.004_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/JCP.0b013e3181e7145f","article-title":"Concordance between measures of functioning, symptoms, and change examining the GAF, CGI-S, CGI-C, and PANSS","volume":"30","author":"Rabinowitz","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2012.11.004_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12003161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12003161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T21:24:16Z","timestamp":1562707456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12003161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0924977X12003161"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.11.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equipercentile linking of the BPRS and the PANSS","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}